Alumis shares jump 82% on Phase 3 success for psoriasis drug
Biotech plans FDA submission for ESK-001 in second half of 2026, marking first potential commercial product
Alumis shares surged nearly 82% after the clinical-stage biotechnology company announced plans to file for regulatory approval of its experimental plaque psoriasis treatment, marking a potential breakthrough for the South San Francisco-based firm that went public just two years ago.
The company confirmed it will submit a New Drug Application to the US Food and Drug Administration in the second half of 2026 for envudeucitinib, also known as ESK-001, after reporting positive Phase 3 trial results demonstrating what executives described as "leading skin clearance" and "meaningful symptom improvement" with a favorable safety profile, according to regulatory filings accompanying the company's year-end financial results.
The stock rally, which propelled Alumis's market capitalization to approximately $3.2 billion, represents a dramatic turnaround for a company that traded as low as $2.76 per share in the past year. Shares closed at $25.38 on Thursday, well above their 50-day moving average of $25.51 and far beyond the 200-day average of $10.31, reflecting investor enthusiasm for the company's first potential commercial product.
ESK-001 is an allosteric tyrosine kinase 2 (TYK2) inhibitor, a class of drugs that has attracted significant attention in the autoimmune disease space. The treatment aims to compete with Bristol Myers Squibb's Sotyktu (deucravacitinib), which generated $1.9 billion in sales in 2024 after winning FDA approval for plaque psoriasis in 2022. Analysts at multiple firms have projected the global psoriasis market could exceed $10 billion annually by 2030.
"The Phase 3 results position ESK-001 as a potential best-in-class TYK2 inhibitor," analysts wrote in recent coverage, noting the drug's differentiated profile could capture significant market share if approved. The consensus analyst rating stands at strong buy, with price targets ranging from $17 to $29 and an average target of $38.80, according to market data.
Beyond psoriasis, Alumis is developing ESK-001 for systemic lupus erythematosus (SLE), a chronic autoimmune disease affecting approximately 1.5 million Americans. The company also has A-005, a central nervous system-penetrant TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases, in its pipeline, along with an interferon regulatory factor 5 (IRF5) program targeting immune dysfunction.
The FDA filing would represent a critical milestone for Alumis, which was founded in 2021 and originally operated as Esker Therapeutics before rebranding in January 2022. The company completed its initial public offering in late 2024, raising approximately $200 million to fund clinical development. Institutional investors now hold 75.2% of outstanding shares.
For a clinical-stage company with just $22.1 million in trailing twelve-month revenue and negative earnings per share of $2.15, securing approval for ESK-001 would transform Alumis into a commercial enterprise. The company reported an operating margin of negative 53.7% over the past year, underscoring the importance of advancing its lead asset toward commercialization.
The second-half 2026 filing timeline aligns with typical FDA review periods, suggesting a potential approval decision in 2027 if the regulatory process proceeds smoothly. Investors will be watching for detailed presentation of the Phase 3 data at upcoming medical conferences, as well as updates on the SLE clinical program, which could expand the drug's commercial opportunity.
Competitive dynamics in the psoriasis market remain intense, with established treatments from AbbVie, Johnson & Johnson, and Novartis dominating current prescribing patterns. However, the oral administration of TYK2 inhibitors offers convenience advantages over injectable biologics, potentially driving physician and patient adoption.
Alumis's financial position, with approximately $439 million in cash and equivalents as of year-end 2025, provides sufficient runway to support the FDA submission process and commercial preparation activities. However, the company will likely need to raise additional capital to fund a potential commercial launch, typical for biotechnology firms transitioning from clinical to commercial stage.